CAI
Caris Life Sciences, Inc. NASDAQ Listed Jun 18, 2025$18.47
+3.42%
vs $17.86
Mkt Cap $30.9B
52w Low $14.55
15.8% of range
52w High $39.30
50d MA $17.75
200d MA $23.89
P/E (TTM)
-9.7x
EV/EBITDA
2676.8x
P/B
53.5x
Debt/Equity
0.7x
ROE
-11.8%
P/FCF
461.7x
RSI (14)
61.90
ATR (14)
$1.03
Beta
1.33
50d MA
$17.75
200d MA
$23.89
Avg Volume
3.1M
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
750 West John Carpenter Freeway · Irving, TX 75039 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.02 | 0.29 | +1550.0% | 19.84 | -15.3% | -18.6% | -1.3% | +5.1% | -12.4% | +3.8% | — |
| Feb 26, 2026 | AMC | -0.02 | 0.28 | +1500.0% | 19.24 | +10.0% | +4.7% | +2.6% | -6.2% | +2.5% | -3.2% | — |
| Nov 5, 2025 | AMC | -0.08 | 0.08 | +200.0% | 29.21 | +2.7% | -15.7% | +4.1% | -3.2% | +1.5% | -1.6% | — |
| Aug 12, 2025 | AMC | -0.21 | -0.54 | -157.1% | 32.46 | +22.6% | +5.6% | +7.9% | -1.3% | -1.5% | +2.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2 | Wolfe Research | Reiterates | Peer Perform | — | $16.45 | $16.05 | -2.4% | +0.4% | -6.3% | +11.6% | -4.6% | -2.1% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $19.29 | $18.97 | -1.7% | -1.5% | -1.4% | +4.1% | -1.6% | -6.0% |
| Mar 13 | Canaccord Genuity | Maintains | Hold → Hold | — | $17.69 | $17.72 | +0.2% | +2.6% | +5.0% | -2.7% | -0.4% | +1.8% |
| Feb 27 | Baird | Maintains | Outperform → Outperform | — | $19.24 | $21.16 | +10.0% | +4.7% | +2.6% | -6.2% | +2.5% | -3.2% |
| Feb 27 | BTIG | Maintains | Buy → Buy | — | $19.24 | $21.16 | +10.0% | +4.7% | +2.6% | -6.2% | +2.5% | -3.2% |
| Feb 27 | Evercore ISI | Maintains | Outperform → Outperform | — | $19.24 | $21.16 | +10.0% | +4.7% | +2.6% | -6.2% | +2.5% | -3.2% |
| Dec 22 | Canaccord Genuity | Maintains | Hold → Hold | — | $27.94 | $28.22 | +1.0% | +1.9% | -1.6% | +0.9% | +0.0% | -1.0% |
| Aug 13 | Citigroup | Maintains | Buy → Buy | — | $32.46 | $39.80 | +22.6% | +5.6% | +7.9% | -1.3% | -1.5% | +2.7% |
| Aug 13 | Evercore ISI | Maintains | Outperform → Outperform | — | $32.46 | $39.80 | +22.6% | +5.6% | +7.9% | -1.3% | -1.5% | +2.7% |
| Aug 13 | Guggenheim | Maintains | Buy → Buy | — | $32.46 | $39.80 | +22.6% | +5.6% | +7.9% | -1.3% | -1.5% | +2.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | Vacirca Jeff LDir | — | Buy | 31,050 | $16.15 | $501K | 49,671 | -12.35% | -0.93% |
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
I need more specific information about the material agreement to provide meaningful analysis. Could you share the actual details of what the material agreement entails (e.g., partnership, acquisition, financing, termination)?
Apr 2
8-K · 7.01
! Medium
Caris Life Sciences, Inc. -- 8-K 7.01: Regulation FD Disclosure
Caris Life Sciences completed an interim readout of its Achieve 1 study supporting Caris Detect, a multi-cancer early detection test slated for near-term launch, signaling progress toward commercialization of its MCED offering.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 30,785,585 | $550M | Added | Mar 2026 |
| 2 | J. H. Whitney Equity Partners Vi, Llc | 18,256,615 | $326M | Reduced | Mar 2026 |
| 3 | Braidwell Lp | 7,816,142 | $211M | Added | Dec 2025 |
| 4 | Coatue Management | 9,819,992 | $176M | — | Mar 2026 |
| 5 | Morgan Stanley | 3,589,982 | $97M | Added | Dec 2025 |
| 6 | Vanguard Portfolio Management Llc | 3,758,462 | $67M | New | Mar 2026 |
| 7 | Neuberger Berman Group Llc | 3,590,586 | $64M | Reduced | Mar 2026 |
| 8 | Vanguard Capital Management Llc | 3,329,021 | $60M | New | Mar 2026 |
| 9 | Jpmorgan Chase & Co | 3,460,215 | $58M | Added | Mar 2026 |
| 10 | Ubs Group Ag | 2,745,811 | $49M | Added | Mar 2026 |
| 11 | Los Angeles Capital Management Llc | 2,289,602 | $41M | Added | Mar 2026 |
| 12 | Duquesne Family Office | 1,894,450 | $34M | New | Mar 2026 |
| 13 | Bnp Paribas Financial Markets | 1,614,286 | $29M | Added | Mar 2026 |
| 14 | Clearbridge Investments, Llc | 1,551,774 | $28M | Added | Mar 2026 |
| 15 | Millennium Management | 1,527,756 | $27M | Reduced | Mar 2026 |
| 16 | Invesco Ltd. | 1,222,278 | $22M | Added | Mar 2026 |
| 17 | Champlain Investment Partners, Llc | 1,207,963 | $22M | Added | Mar 2026 |
| 18 | Capital World Investors | 1,180,173 | $21M | New | Mar 2026 |
| 19 | Point72 Asset Management | 918,331 | $16M | Reduced | Mar 2026 |
| 20 | Seven Grand Managers, Llc | 495,095 | $13M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$30.88B
Enterprise Value
$30.46B
P/E (TTM)
-9.72x
Forward P/E
153.28x
PEG Ratio
2.83x
P/B
53.49x
P/S
38.03x
P/FCF
461.66x
EV/EBITDA
2676.77x
Shares Out
1.67B
Financials (TTM)
Revenue
$812.0M
Net Income
-$538.0M
EBITDA
$11.4M
Free Cash Flow
$66.9M
Op Cash Flow
$83.2M
EPS Basic
$-1.90
EPS Diluted
$-1.90
EPS Forward
$0.12
Gross Margin
66.4%
Op Margin
5.6%
Net Margin
-66.2%
Balance Sheet
Total Assets
$1.13B
Total Liab.
$548.4M
Total Equity
$577.3M
Cash
$800.1M
LT Debt
$378.8M
Book Value/Sh
$0.35
Debt/Equity
0.66x
Current Ratio
7.85
Quick Ratio
7.85
Returns & Growth
ROE
-11.8%
ROA
-6.0%
ROIC
4.5%
Rev Growth YoY
+97.0%
EPS Growth YoY
+29.6%
Price Returns
2W
+9.6%
1M
-12.0%
3M
-17.0%
6M
-34.5%
12M
-40.3%
Technicals
52W High
$39.30
52W Low
$14.55
50d MA
$17.75
200d MA
$23.89
RSI (14)
61.90
ATR (14)
$1.03
Beta
1.33
Avg Volume
3.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Sep 9, 2021
Analyst Price Targets
Consensus
$28.75
High
$38.00
Low
$21.00
Median
$28.00
Data updated apr 24, 2026 11:41pm
· Source: financialmodelingprep.com